
CLAIMS

What is claimed is:

1. Use of a pharmaceutical composition in the manufacture of a medicament for treating adenoid cystic carcinoma in a subject in need thereof, wherein the pharmaceutical composition comprises a benzenesulfonamide derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, wherein the benzenesulfonamide derivative is represented by formula (I):



(I),

























or a pharmaceutically acceptable salt thereof,

wherein R_1 to R_7 are independently selected from the group consisting of H, a C_1-C_6 linear or branched alkyl group, a C_1-C_6 linear or branched alkoxy group, a C_3-C_6 cycloalkyl group, a C_3-C_6 cycloheteroalkyl group, an amino group, and a halo group, or R_6 and R_7 are linked to each other to form a ring, and

wherein the alkyl, alkoxy, cycloalkyl, cycloheteroalkyl groups and the ring are unsubstituted or substituted with one or more substituents.

2. The use of claim 1, wherein the substituent is selected from the group consisting of phenyl, halo, oxo, ether, hydroxyl, carboxyl, amino, sulfo and sulfonamide group.
























3. The use of claim 1, wherein the benezesulfonamide derivative or the pharmaceutically acceptable salt thereof is at least one selected from the group consisting of para-toluene sulfonamide, ortho-toluene sulfonamide, meta-toluene sulfonamide, N-ethyl ortho-toluene sulfonamide, N-ethyl para-toluene sulfonamide, N-cyclohexyl para-toluene sulfonamide,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,


,

,



,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

HCl
,



,


, and



.

4. The use of claim 1, wherein the pharmaceutical composition has a viscosity of from 20 to 200 cP.

5. The use of claim 4, wherein the pharmaceutical composition has the viscosity of from 40 to 60 cP.

6. The use of claim 5, wherein the pharmaceutical composition has the viscosity of from 47.2 to 48.4 cP.

7. The use of claim 1, wherein the pharmaceutically acceptable carrier is selected from the group consisting of polyethylene glycol (PEG), alkylene glycol, sebacic acid, dimethyl sulfoxide (DMSO), alcohol and a combination thereof.

8. The use of claim 7, wherein the alkylene glycol is at least one of 2-ethyl-1,3-hexandiol and propanediol.

9. The use of claim 1, wherein the benzenesulfonamide derivative is present in an amount of from 10% to 50% by weight.

10. The use of claim 9, wherein the benzenesulfonamide derivative is present in an amount of from 20% to 40% by weight.

11. The use of claim 9, wherein the pharmaceutical composition further comprises at least one of 20% to 50% by weight of PEG, 5% to 15% by weight of propanediol, 1% to 5% by weight of sebacic acid, 10% to 20% by weight of 2-ethyl-1,3-hexanediol, 5% to 10% by weight of dimethyl sulfoxide and anhydrous ethanol in a range of from 0%, not included, to 30% by weight.

12. The use of claim 11, wherein the pharmaceutical composition comprises the benezesulfonamide derivative in an amount of about 33% by weight, the PEG in an amount of about 35.5% by weight, the 2-ethyl-1,3-hexandiol in an amount of about 16.4% by weight, the propanediol in an amount of about 8.2% by weight, the sebacic acid in an amount of about 3.7% by weight, and the DMSO in an amount of about 6.7% by weight.
13. The use of claim 1, wherein the pharmaceutical composition is to be administered to the subject intratumorally, intravenously, subcutaneously, intradermally, intrathecally, intraperitoneally, intramuscularly, or intrapleuraly.
14. The use of claim 13, wherein the pharmaceutical composition is to be administered to the subject by a needling instrument having an 18G needle.
15. The use of claim 1, wherein the adenoid cystic carcinoma is tracheal adenoid cystic carcinoma.
16. The use of claim 1, wherein the benzenesulfonamide derivative in the pharmaceutical composition is to be administered to the subject in a therapeutically effective amount of from about 1000 mg to about 3300 mg per day.
17. The use of claim 1, wherein the pharmaceutical composition is to be administered to the subject 1 to 4 times per week.
18. The use of claim 1, wherein the pharmaceutical composition is to be administered to the subject for a 1- to 3-week treatment period.